Ryan Morse, M.D.

Dr. Ryan Morse is a radiation oncologist at the University of Kansas Cancer Center and an Assistant Professor at the University of Kansas School of Medicine. He specializes in the management of gastrointestinal cancers, head and neck cancers, skin cancer, and breast cancer. After completing his Bachelor of Science at Missouri University of Science and Technology, Dr. Morse went on to complete his Doctor of Medicine at the University of Kansas School of Medicine, where he stayed to complete his internship in the Department of Internal Medicine. Dr. Morse completed his radiation oncology training at the University of North Carolina at Chapel Hill, serving his final year as Chief Resident.

Dr. Morse’s research primarily focuses on quality of life and patient reported outcomes in older adults diagnosed with cancer. He believes that cancer treatments need to be optimized to better fit the needs of older patients, and he wishes to dedicate his clinical and research career to this problem. At the University of North Carolina, Dr. Morse completed a two-year NIH-funded T32 training grant in Geriatric Oncology. He is one of few radiation oncologists in the US who have undergone formal fellowship training in geriatric oncology.

Dr. Morse is committed to being an investigative, academic radiation oncologist and clinical trialist. He has achieved early career success by receiving several awards and grants for his clinical excellence and research. By obtaining formal training in clinical trial design/development at the ASCO “Vail” Workshop, he has been instrumental in developing several prospective protocols, aiming to expand treatment options in older adults. Most recently, he has been awarded the ASCO 2024 Conquer Cancer Endowed Young Investigator Award in Geriatric Oncology in Honor of Dr. Arti Hurria, to study the benefit of local radiation therapy in older patients with breast cancer who are ineligible or decline surgery.

Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.

Hypoxic Cell Radiosensitization in Head and Neck Squamous Cell Carcinoma: Running Out of Air.

Interplay of Oncoplastic Reconstruction and Adjuvant Radiation Therapy in Breast Cancer.

Neoadjuvant Radiotherapy Facility Type Affects Anastomotic Complications After Esophagectomy.

Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty.

Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.